drugset

drugset / Trial / NCT00047567

Open-label Adjunctive Zonisamide for Bipolar Disorder

NCT00047567 ↗

Phase 4 Terminated 20 enrolled Elan Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.

Timeline

Start: 2002-07
Primary completion: —
Completion: 2002-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zonisamide	Other / unclassified	—	—

Indications